Camurus Oclaiz Dec 18 PDUFA: 85% Approval Odds

Camurus (OTC: CAMRF; Nasdaq Stockholm: CAMX) faces a December 18 PDUFA for Oclaiz, its once-monthly octreotide depot for acromegaly. The FDA has already told Camurus twice that the clinical case is fine. Both complete response letters cited the same third-party manufacturing facility, never the efficacy or safety data. Approval odds sit at about 85 percent. The problem is that winning approval is not the same as winning the market. Vertex paid $10 billion for Crinetics in July to own Palsonify, the first once-daily oral acromegaly pill. Camurus is about to win approval for a better injection at the exact moment the market is moving to pills.

The company: profitable, and this drug is incremental

Camurus is not a pre-revenue biotech betting everything on one PDUFA. It is a profitable Swedish specialty pharma that booked SEK 702 million in total revenue in Q2 2026, up 4 percent year over year, with an operating result of SEK 293 million, a 42 percent margin. The company guided to SEK 2.6 to 2.9 billion in 2026 revenue, roughly $260 to $290 million at current exchange rates, up about 21 percent at the midpoint. The franchise is buprenorphine for opioid use disorder: Buvidal in Europe and Brixadi in the US, where Braeburn pays Camurus a royalty that grew 42 percent in Q2 to SEK 127 million. The stock carries a market cap of about $3.7 billion, so it trades near 13 times forward revenue for a business growing 21 percent with a 42 percent operating margin.

That context matters more than the headline. Oclaiz is an incremental growth driver on top of a compounding buprenorphine franchise, and that distinction determines how the stock reacts on December 18.

The drug: real clinical data, real differentiation

Oclaiz, known as CAM2029, is octreotide, the same somatostatin analogue Novartis launched as Sandostatin in 1988. The difference is delivery. Camurus’s FluidCrystal formulation turns octreotide into a once-monthly subcutaneous depot delivered by a prefilled autoinjector pen. That matters on two counts. It removes the need for a monthly intramuscular injection into the gluteal muscle, which is how Sandostatin LAR is given. And it delivers roughly five times the bioavailability of intramuscular octreotide, which is why the dose can be smaller and the needle subcutaneous.

The Phase 3 data is strong. In ACROINNOVA 1, the 24-week placebo-controlled trial of 72 patients, Oclaiz produced an IGF-1 response rate of 72.2 percent versus 37.5 percent for placebo, a p-value of 0.0018. IGF-1 is the biomarker endocrinologists use to judge whether acromegaly is controlled, so this is the endpoint that decides the label. The key secondary endpoint, the share of patients with both normalized IGF-1 and a mean growth hormone below 2.5 micrograms per liter, also favored the drug, and patients reported better symptom control, quality of life, and treatment satisfaction than they had on baseline standard of care. ACROINNOVA 2, the 52-week open-label extension in 135 patients, confirmed the safety profile and showed a 12.7 percentage point improvement in biochemical response versus baseline standard of care, rising to 22.8 points in newly enrolled patients. The drug is already approved in the EU and UK as Oczyesa, and the trial data lives on ClinicalTrials.gov under ACROINNOVA 1.

The regulatory path: two CRLs, zero clinical concerns

Here is the full history. Camurus filed the original NDA in December 2023. The FDA issued a CRL in October 2024 citing facility deficiencies from a September 2024 cGMP inspection of a third-party manufacturer. Camurus resubmitted in January 2026. In June 2026 the FDA issued a second CRL, this time citing the same facility observations plus a labeling change to the oxygen absorber in the packaging. Both letters explicitly said nothing about clinical efficacy or safety. The resubmission was accepted July 17 with a December 18 PDUFA.

This is the cleanest possible rejection pattern in biotech: a drug whose science is done, held up by a manufacturing checklist. The same pattern just played out at ITM, whose 177Lu-edotreotide got a CRL for manufacturing-only issues with a clean Phase 3 win. The risk is real but narrow: the facility has to actually be fixed this time, and a third CRL is possible if it is not. That is why the odds are capped at 85 percent rather than 95.

The competitive picture: the war is over, and it went oral

This is where the thesis gets uncomfortable for Camurus bulls. Oclaiz is a better injection. The market has already moved to pills.

Vertex closed its $10 billion acquisition of Crinetics in Q3 2026, paying roughly 143 times Crinetics’ annualized revenue to own Palsonify, the first once-daily oral somatostatin receptor agonist approved for acromegaly. Palsonify launched in October 2025 after a September 2025 approval, and consensus sees it reaching $649 million by 2030 and $1 billion by 2034, per S&P Global. The launch has been slow out of the gate, booking just $10.3 million in product revenue in Q1 2026, which is why the $649 million target requires a sixtyfold ramp. That slow start is the one sliver of hope for an injectable like Oclaiz: oral adoption is not instantaneous, and a meaningful share of patients will stay on injections for years. Chiesi’s Mycapssa, an oral octreotide capsule, has been on the market since 2020. Sandostatin LAR is generic. Somatuline, Ipsen’s lanreotide, still matters but is another injectable fighting the same headwind.

Oclaiz’s value proposition is real but narrower than it looks. For patients who want to stay on an injectable, a once-monthly subcutaneous autoinjector with five times the bioavailability is a genuine upgrade over an intramuscular gluteal shot. That is a real niche. It is not the $649 million opportunity Palsonify is chasing.

Valuation: what the approval is actually worth

Camurus trades at roughly $3.7 billion, about 13 times forward revenue, for a profitable business growing 21 percent. The acromegaly opportunity is a fraction of that. The entire acromegaly market across the seven major markets is about $1.3 billion, with the US the largest single slice. If Oclaiz reaches $200 million in US peak sales, an optimistic outcome given the oral competition, that is worth perhaps $600 million at a three times peak sales multiple, about 16 percent of the current market cap. If the oral class caps Oclaiz at $100 million, the incremental value is closer to $300 million, or 8 percent.

Compare that to what Vertex paid. The market already told you what the oral class is worth: the $10 billion Crinetics deal for Palsonify plus the endocrine pipeline. That is the multiple applied to pills. Injections do not get that multiple. Camurus is priced mostly for Brixadi and Buvidal, and the December 18 approval moves the needle by single digits to low teens, not by a double.

Risks

The specific risk is not clinical. It is the same facility that has already produced two CRLs. If the third-party manufacturer has not fully resolved the September 2024 cGMP observations, the FDA can issue a third CRL and the stock gives back whatever it priced in. The commercial risk is Palsonify: Vertex will market the first oral aggressively, and every patient who switches to a pill is a patient Oclaiz never gets. For US investors there is also a structural caveat: Camurus’s primary listing is Nasdaq Stockholm, and the only US access is the OTC ticker CAMRF, which trades thinly. The catalyst is real; the pure play is inconvenient to buy.

The bigger pattern

Camurus is part of a 2026 pattern the FDA keeps repeating. When a drug’s clinical data is settled but a third-party facility fails inspection, the agency issues a CMC-only CRL that resets the clock without resetting the science. ITM’s 177Lu-edotreotide got the same treatment, and both companies simply refiled with no new patient data. For investors the lesson is that a manufacturing finding is not a failed endpoint. The drug’s value stays intact, and the only question is how fast the facility problem gets fixed. That is a much better problem to have than a trial that missed, and it is why these CRLs usually end in approval rather than withdrawal.

Verdict

Approval odds sit at 85 percent, with a modest single-digit to low-teens move expected if it clears. The clinical case is settled and the EU already approved the drug, but Oclaiz is a better injection entering a pill market, and Vertex’s $10 billion bet is the tell. If you want acromegaly exposure, the trade is Vertex through Palsonify, not Camurus through Oclaiz. Camurus remains a hold for the Brixadi and Buvidal compounding story, where December 18 is a rounding event rather than a thesis.